adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v
Company profile
Ticker
ACET
Exchange
Website
CEO
Chen Schor
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
resTORbio, Inc.
SEC CIK
Corporate docs
Subsidiaries
Adicet Therapeutics, Inc. • Adicet Bio Israel Ltd. ...
ACET stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
22 Mar 24
424B5
Prospectus supplement for primary offering
22 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 24
S-8
Registration of securities for employees
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
19 Mar 24
8-K
Adicet Bio, Inc. Announces Proposed Public Offering
24 Jan 24
424B5
Prospectus supplement for primary offering
24 Jan 24
424B5
Prospectus supplement for primary offering
22 Jan 24
8-K
Regulation FD Disclosure
16 Jan 24
Latest ownership filings
SC 13D/A
ORBIMED ADVISORS LLC
21 Mar 24
SC 13G
MILLENNIUM MANAGEMENT LLC
27 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G
MORGAN STANLEY
12 Feb 24
SC 13G/A
BlackRock Inc.
7 Feb 24
SC 13D/A
Carlyle Group Inc.
7 Feb 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
5 Feb 24
SC 13G/A
Cowen Financial Products LLC
2 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 183.26 mm | 183.26 mm | 183.26 mm | 183.26 mm | 183.26 mm | 183.26 mm |
Cash burn (monthly) | 7.40 mm | 8.29 mm | 17.42 mm | 12.67 mm | 7.08 mm | 7.42 mm |
Cash used (since last report) | 44.32 mm | 49.61 mm | 104.31 mm | 75.87 mm | 42.39 mm | 44.44 mm |
Cash remaining | 138.94 mm | 133.65 mm | 78.95 mm | 107.39 mm | 140.87 mm | 138.81 mm |
Runway (months of cash) | 18.8 | 16.1 | 4.5 | 8.5 | 19.9 | 18.7 |
Institutional ownership, Q3 2023
52.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 87 |
Opened positions | 13 |
Closed positions | 24 |
Increased positions | 30 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 47.57 bn |
Total shares | 43.24 mm |
Total puts | 20.70 k |
Total calls | 2.60 k |
Total put/call ratio | 8.0 |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 8.32 mm | $11.40 bn |
RTW Investments | 4.24 mm | $5.81 bn |
MS Morgan Stanley | 3.84 mm | $5.26 bn |
Cowen Financial Products | 3.14 mm | $28.10 mm |
Cowen And | 2.72 mm | $3.72 bn |
Tang Capital Partners | 2.27 mm | $17.67 mm |
BLK Blackrock | 2.27 mm | $3.11 bn |
CG Carlyle Group Inc | 2.12 mm | $2.88 bn |
Vanguard | 1.67 mm | $2.29 bn |
Novartis Bioventures | 1.37 mm | $22.90 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Jan 24 | Orbimed Advisors | Common Stock | Buy | Acquire P | Yes | No | 2.4 | 1,041,700 | 2.50 mm | 1,255,985 |
25 Jan 24 | Orbimed Advisors | Common Stock | Buy | Acquire P | Yes | No | 2.4 | 242,200 | 581.28 k | 990,254 |
25 Jan 24 | Orbimed Advisors | Common Stock | Buy | Acquire P | Yes | No | 2.4 | 1,841,100 | 4.42 mm | 7,526,359 |
25 Jan 24 | Gordon Carl L | Common Stock | Buy | Acquire P | Yes | No | 2.4 | 1,041,700 | 2.50 mm | 1,255,985 |
25 Jan 24 | Gordon Carl L | Common Stock | Buy | Acquire P | Yes | No | 2.4 | 242,200 | 581.28 k | 990,254 |
25 Jan 24 | Gordon Carl L | Common Stock | Buy | Acquire P | Yes | No | 2.4 | 1,841,100 | 4.42 mm | 7,526,359 |
24 Jan 24 | Francesco Galimi | Common Stock | Grant | Acquire A | No | No | 0 | 26,300 | 0.00 | 101,801 |
24 Jan 24 | Francesco Galimi | Common Stock | Payment of exercise | Dispose F | No | No | 2.4 | 4,957 | 11.90 k | 75,501 |
24 Jan 24 | Francesco Galimi | Stock Option Common Stock | Grant | Acquire A | No | No | 2.4 | 288,134 | 691.52 k | 288,134 |
24 Jan 24 | Blake Aftab | Common Stock | Grant | Acquire A | No | No | 0 | 19,700 | 0.00 | 62,511 |
News
HC Wainwright & Co. Reiterates Buy on Adicet Bio, Maintains $10 Price Target
20 Mar 24
Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target
20 Mar 24
Canaccord Genuity Reiterates Buy on Adicet Bio, Maintains $19 Price Target
20 Mar 24
Adicet Bio: Q4 Earnings Insights
19 Mar 24
Adicet Bio Q4 2023 GAAP EPS $(0.69) Beats $(0.70) Estimate
19 Mar 24
Press releases
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
28 Mar 24
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
21 Mar 24
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
29 Feb 24
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
5 Feb 24
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
31 Jan 24